Latest News and Press Releases

This trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from negative chemotherapy-induced side effects.

Las Vegas, Nevada, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Crucial Innovations Corp (OTC: CINV), a Nevada Company today announced that has completed its previously announced reverse merger by acquiring...

Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...

Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...

VARUBI injectable emulsion features a ready-to-use, single-dose vial for intravenous administrationAvailability of new formulation offers healthcare providers the flexibility to choose oral or IV...

VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...

WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...

WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of five abstracts at the 2016...

WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...

WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...